Diagnosis and treatment progress of chronic myeloid leukemia / 白血病·淋巴瘤
Journal of Leukemia & Lymphoma
; (12): 6-8, 2020.
Article
en Zh
| WPRIM
| ID: wpr-799283
Biblioteca responsable:
WPRO
ABSTRACT
Chronic myeloid leukemia (CML) has made a milestone progress due to the development of the first generation tyrosine kinase inhibitor(TKI). Nowadays, most clinical trials in CML focus on discontinuation, even the second discontinuation, and the third generation TKI against T315I mutation. The conventional treatments are more focused on decreasing BCR-ABL transcripts rapidly. At the same time, the treatment management of some special patients has been valued.
Texto completo:
1
Base de datos:
WPRIM
Tipo de estudio:
Diagnostic_studies
Idioma:
Zh
Revista:
Journal of Leukemia & Lymphoma
Año:
2020
Tipo del documento:
Article